Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...

The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

More than 60 billion euros (£52 billion) has been wiped off the stock market value of Ozempic and Wegovy weight loss drug firm Novo Nordisk after it warned over sales and profits ...

Shares of Danish drugmaker Novo Nordisk (NVO) traded 8% lower on Wednesday afternoon after the company slashed its full-year ...

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...